Clinical Trial Search

Primary: Annualized Relapse Rate Before Cetirizine — 0.4; 0.1 relapses per year

Primary: Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP — NA; NA Days — p=<0.0001

Primary: Median Number of Neuromyelitis Optica (NMO) Attacks Per Year — 3; 0 attacks per year — p=<0.0001

Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 162; 44 Participants

Primary: Annual Relapse Rate — 1; 1.30; 0.51; 0.21 Number of relapses

Primary: Time to First Protocol-Defined Relapse (TFR) in the Double-Blind Period — 120.6; NA weeks — p=0.0184

Primary: Time to First Protocol-Defined Relapse (TFR) During the Double-Blind (DB) Period — 128.3; NA weeks — p=0.0184

Primary: Number of Adverse Safety Events During Hospitalization — 0 adverse safety events

Primary: Baseline Expanded Disability Status Score (EDSS) — 3.5 units on a scale

Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events — 41; 70; 14; 26 Participants

Primary: Change in Pain Score on the Numerical Rating Score (NRS) — 2.2; 1.3 units on a scale

Primary: Efficacy of Dalfampridine on Visual Function by Early Diabetic Treatment Retinopathy Study (EDTRS) 5% Contrast Sensitivity Scores — -0.04; -0.06; -0.08; -0.06 LogMAR…

Primary: Number of Participants With an Adjudicated On-trial Relapse in the Primary Treatment Period — 0; 20 Participants — p=< 0.0001

Primary: Pulse Size Ratio (PSR): Abducting/Adducting Eye Ratio for Saccadic Peak Velocity. — 1.914; 1.937; 1.805; 1.898 ratio — p=0.842672

Primary: Acceptability as Assessed by the Number of Participants Responding Yes to a Question — 7; 5 Participants

Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci

Primary: Change in Full-field Visual Evoked Potential (FF-VEP) Latency at Week 24: Intent-to-treat (ITT) Population — 20.83; 17.34 msec — p=0.3337

Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months

Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003

Primary: Change in Visual Acuity — 4; 3 lines change in Snellen chart

Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: FF-VEP Latency of the Affected Eye as Compared to the Baseline of the Fellow Eye at 2 Years (+ up to 12 Months) After the Last Study Visit Assessment (Week 32) in RENEW…

Primary: Pain Intensity — 5.82; 4.92 score on a scale

Primary: Change From Baseline in Visual Acuity at 9 Month — -0.0574; 0.0535 LogMAR

Primary: Survival — 13; 12; 12; 11 Participants

Primary: Number of Participants Off Drug That Have New Inflammatory Disease Compared to Those on Drug. — 2; 1 Participants — p=0.124

Primary: Walking Speed During Timed 25-foot Walk — 0.3342; 0.4745; 0.4593; 0.1743 feet/second

Primary: Retinal Nerve Fiber Layer Thickness at Baseline and Month 6 — 128.1; 130.5; 89.5; 88.0 µm